Cinryze

Type: Product
Name: Cinryze
First reported Jul 22 2014 - Updated Jul 22 2014 - 2 reports

ABBVIE : Shire Reports Revenue Of $1.5 Billion In Q2 2014

Shire reported a total revenue of $2.84 billion for the six months ended June 30, 2014 compared to $2.4 billion in the same period of 2013. Net income was $753.5m for the six months ended June 30, 2014 , compared to $322.9m in the same period of 2013 ... [Published 4 Traders - Jul 22 2014]
First reported Jul 20 2014 - Updated Jul 20 2014 - 1 reports

Shire’s strong 2nd-qtr financials justify holding out for higher AbbVie bid

Ireland-headquartered drugmaker Shire (LSE: SHP), which has just  accepted an increased $54 billion bid from the USA’s AbbVie (NYSE: ABBV), has delivered record second-quarter 2014 financial results, justifying its four times rejection of prior offers. ... [Published Pharma Letter - Jul 20 2014]
First reported Jul 19 2014 - Updated Jul 20 2014 - 1 reports

Shire sales growth shows why AbbVie was attracted

In what could be its penultimate set of financials before being merged into AbbVie, Shire has posted a strong set of second-quarter figures.Operating income jumped 32% to $630 million, while revenues rose 20% to $1.50 billion. Turnover was again driven ... [Published Pharma Times - Jul 19 2014]
First reported Jul 18 2014 - Updated Jul 19 2014 - 2 reports

Shire Delivers Record Quarterly Revenues and Non GAAP Diluted Earnings per ADS up 42%

SOURCE Shire plcDUBLINNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.Increases Non GAAP diluted earnings per ADS ... [Published WTNZ - Jul 18 2014]
First reported Jul 19 2014 - Updated Jul 19 2014 - 1 reports

US drugs giant finally seals £32bn takeover of Shire

The FTSE 100 big-pharma player Shire celebrated a £32bn takeover by US suitor AbbVie with record results as the two companies beat a Takeover Panel deadline to agree a firm offer. The UK firm unveiled a 22 per cent rise in quarterly revenues to a record ... [Published The Independent - Jul 19 2014]
First reported Jul 18 2014 - Updated Jul 19 2014 - 1 reports

Shire’s Q2 net income more than doubles, buoyed by ViroPharma deal, Vyvanse sales

Shire announced Friday that net income for the second quarter more than doubled to $523.1 million, from $258.1 million in the year-ago period, boosted in part by the $4.2-billion acquisition of ViroPharma. Flemming Orsnkov, CEO of Shire, which agreed ... [Published FirstWord Pharma - Jul 18 2014]
First reported Jul 18 2014 - Updated Jul 19 2014 - 1 reports

FDA approves drug for rare swelling diseases

US regulators this week approved a new drug derived from the milk of genetically-modified rabbits to treat a rare swelling disorder.Ruconest is developed in partnership by Salix Pharmaceutical and Pharming and is intended as a protein replacement in people ... [Published PMLive - Jul 18 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 2 reports

Will Congress Scuttle the AbbVie-Shire Merger?

ReutersAbbVie’s (ABBV) $54 billion proposal to acquire Irish drug maker Shire (SHPG) would mark the largest tax inversion ever, as a growing number of U.S. companies pursue lower rates overseas.After months of courtship and four offers, AbbVie sealed ... [Published FOXBusiness.com - Jul 18 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

Halozyme Attracting Attention With Upcoming Adcom And Potential Blockbuster Pancreatic Cancer Treatment

Summary Halozyme and Baxter Pharma have a Food and Drug Administration (FDA) Advisory Committee (adcom) meeting coming up on July 31. The adcom will give guidance on whether Halozyme's Biologics License Application (BLA) for its Human Immune Globulin ... [Published Seeking Alpha - Jul 08 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 2 reports

SHIRE PLC - The Path to US$10 Billion in Product Sales by 2020

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. For immediate release 23 June 2014 Shire plc The Path to US$10 ... [Published FinanzNachrichten.de - Jun 23 2014]
First reported Jun 20 2014 - Updated Jun 20 2014 - 4 reports

AbbVie’s Shire Push Won’t Face Pfizer Hurdles in U.K. Takeover

June 20 (Bloomberg) -- Shire Plc became one of the hottest properties in health care by buying promising drugs instead of developing them in-house. That may help AbbVie Inc. avoid the pitfalls that bedevilled Pfizer Inc.’s bid for AstraZeneca Plc.U.S. ... [Published Washington Post - Jun 20 2014]
First reported May 01 2014 - Updated May 02 2014 - 2 reports

Shire lifts guidance; silent on M&A buzz

Shares in Shire ( LON:SHP ) were given a shot in the arm after the drugmaker lifted its profit guidance and unveiled the acquisition of Australian biotech Fibrotech. First quarter revenues were up 18% at US$1.35bn, with non-GAAP earnings per share up ... [Published Proactiveinvestors United Kingdom RSS feed - May 01 2014]

Quotes

Flemming Ornskov , M D , Shire's Chief Executive Officer, commented: " We have again delivered record quarterly result s, with product s ales growing by 22%, N on GAAP diluted earnings per ADS growth of 42% and Non GAAP cash generation of $659 million . We have also again increased our expectations for earnings growth in 2014 ."
...Dr Flemming Ornskov, Shire's chief executive officer, said: "These results and our increased guidance highlight the benefits of our strategic focus on high-growth areas. This performance is a testament to the value AbbVie sees in our company."
...5bn (£877m) and upgraded profit targets for the year as its chief executive Flemming Ornskov called the performance "a testament to the value AbbVie sees in our company"
Ornskov noted that "our 2014 performance to date means that we are taking an important early stride towards meeting our target of $10 billion in product sales by 2020, a target which excludes revenues from our two latest acquisitions, Lumena and Fibrotech." The May acquisition of Lumena Pharmaceuticals is expected to boost the company’s rare disease pipeline with drugs for gastrointestinal and hepatic c...

More Content

All (38) | News (36) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Shire's Q2 Earnings Strong but Overshadowed b… [Published Zacks.com - Jul 22 2014]
ABBVIE : Shire Reports Revenue Of $1.5 Billion ... [Published 4 Traders - Jul 22 2014]
Shire reports record results for Q2 2014 [Published Zenopa - Jul 22 2014]
Shire’s strong 2nd-qtr financials justify holdi... [Published Pharma Letter - Jul 20 2014]
Shire sales growth shows why AbbVie was attracted [Published Pharma Times - Jul 19 2014]
Shire Delivers Record Quarterly Revenues and No... [Published Red Orbit - Jul 19 2014]
US drugs giant finally seals £32bn takeover of ... [Published The Independent - Jul 19 2014]
Will Congress Scuttle the AbbVie-Shire Merger? [Published FOXBusiness.com - Jul 18 2014]
Shire’s Q2 net income more than doubles, buoyed... [Published FirstWord Pharma - Jul 18 2014]
AbbVie and Shire come to terms on a $55B union [Published FierceBiotech - Jul 18 2014]
FDA approves drug for rare swelling diseases [Published PMLive - Jul 18 2014]
Shire Delivers Record Quarterly Revenues and No... [Published WTNZ - Jul 18 2014]
Shire Delivers Record Quarterly Revenues and No... [Published Indianapolis Business Journal - Jul 18 2014]
AbbVie coaxes Shire into discussions with sweet... [Published PMLive - Jul 14 2014]
UPDATED: Intent on closing a deal, AbbVie boost... [Published FierceBiotech - Jul 08 2014]
Halozyme Attracting Attention With Upcoming Adc... [Published Seeking Alpha - Jul 08 2014]
Spark Therapeutics Appoints Industry Leaders La... [Published Pharmacy Choice - Jul 03 2014]
Voyager Therapeutics Appoints Industry Veteran ... [Published Pharmacy Choice - Jun 27 2014]
Voyager Therapeutics Appoints Industry Veteran ... [Published BioPortfolio - Jun 26 2014]
Spark Therapeutics Appoints Industry Leaders La... [Published HispanicBusiness.com - Jun 26 2014]
Shire share price climbs higher on pledge to do... [Published City A.M. - Jun 23 2014]
Monday’s Top Biotech Stocks to Watch: Rockwell,... [Published Motley Fool - Jun 23 2014]
SHIRE PLC - The Path to US$10 Billion in Produc... [Published FinanzNachrichten.de - Jun 23 2014]
Shire plc The Path to US$10 Billion in Product ... [Published ADVFN UK - Jun 23 2014]
Here's Why AbbVie Wants to Cozy Up With Shire [Published Motley Fool Discussion Boards - Jun 23 2014]
AbbVie’s Shire Push Won’t Face Pfizer Hurdles i... [Published Washington Post - Jun 20 2014]
AbbVie Says Shire Plc Has Rejected Its $46.5 Bi... [Published Bidness Etc - Jun 20 2014]
AbbVie says Shire has spurned three buyout offe... [Published FierceBiotech - Jun 20 2014]
Shire plc Shire Confirms Rejection of AbbVie Pr... [Published ADVFN UK - Jun 20 2014]
Shire plc: Reported To Hire Takeover Adviser [Published Value Walk - Jun 19 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Rarefied Air of Rare Disease Drug Pricing [Published The Big Red Biotech Blog - Feb 20 2014]
BioMarin has set the price for its newly approved drug Vimizim, a treatment for Moquito A syndrome, at $380,000 per year. At that price, it expects to garner about $500 M in annual sales and the drug clocks in with the 3rd highest overall drug price. ...
Is This Analyst Wrong About Halozyme? [Published Wall St. Cheat Sheet - Jan 27 2014]
Every once in a while, there is an event that makes investors scratch their heads. While most investors don’t base their investing decisions solely off sell-side upgrades/downgrades, it is still interesting to read them in order to perhaps gain ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.